Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
AssigneeBoard of Regents, The University of Texas System
InventorsGregory R. Mundy, Toshiyuki Yoneda
Life of this patent
Estimating the term…
Abstract
Antagonists of α4 integrin/α4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their α4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
Claims50
A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an antagonist of an interaction between an α4 subunit-bearing integrin and a ligand for an α4 subunit-bearing integrin.
A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a first composition comprising an antagonist of an interaction between an α4 subunit-bearing integrin and a ligand for an α4 subunit-bearing integrin, wherein said first composition is administered in combination with a therapeutically effective amount of a second composition comprising a compound that is not an antagonist of an interaction between an α4 subunit-bearing integrin and a ligand for an α4 subunit-bearing integrin.
A method for inhibiting bone resorption associated with tumors of bone marrow, the method comprising administering to a mammal with said tumors an antagonist of an interaction between an α4 subunit-bearing integrin and a ligand for an α4 subunit-bearing integrin, in an amount effective to provide inhibition of said bone resorption.
A method of treating a subject having a disorder characterized by the presence of osteoclastogenesis, the method comprising administering to the subject an antagonist of an interaction between an α4 subunit-bearing integrin and a ligand for an α4 subunit bearing integrin, in an amount sufficient to suppress the osteoclastogenesis.
Dependencies are inferred from the claim text.